Skip to main content

Table 4 Overall Best Response Per RECIST V 1.1 and for Patients with Metformin Duration of > 5 Months (PR = Partial Response, CR = Complete Response, SD = Stable Disease, PD = Progressive Disease, ORR = Objective Response Rate, DCR = Disease Control Rate)

From: Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma

All Patients No Metformin N = 33 (60%) Metformin N = 22 (40%)  
Best Response
 PR 14 (42.4%) 9 (40.9%) P = 0.39
 CR 4 (12.1%) 6 (27.27%)
 SD 2 (6%) 2 (9.1%)
 PD 13 (39.4%) 5 (22.7%)
ORR 54.5% 68.2% P = 0.31
DCR 60.6% 77.3% P = 0.19
Median Time to Achieve Best Response (months) 2.7 2.8 P = 0.12
Metformin Duration of > 5 Months No Metformin N = 33 (67.3%) Metformin N = 16 (32.7%)  
Best Response
 PR 14 (42.4%) 5 (31.2%) P = 0.12
 CR 4 (12.1%) 6 (37.5%)
 SD 2 (6%) 2 (12.5%)
 PD 13 (39.4%) 3 (18.8%)
ORR 54.5% 68.7% P = 0.34
DCR 60.6% 81.3% P = 0.14
Median Time to Achieve Best Response (months) 2.7 3 P = 0.11